ABSTRACT
AIM: To investigate the clinical effect of compound anisodine on patients with paralytic strabismus and the influence on malondialdehyde ( MDA ) and superoxide dismutase ( SOD) . ●METHODS: Seventy cases diagnosed with paralytic strabismus from Jun. 2008 to Dec. 2014 were selected as treatment group; another 70 cases with paralytic strabismus from Oct. 2000 to Jan. 2008 were chosen as control group. The control group was given with conventional therapy, and treatment group was additionally injected with compound anisodine subcutaneously on the basis of the control group. Treatment lasted for two courses about 28days. The effect of compound anisodine on patients with paralytic strabismus was evaluated and the serum level of MDA and SOD was also measured before and after treatment. ●RESULTS: ln treatment group, 54 cases were cured (77%), 14 cases improved (20%) and 2 cases had no response ( 3%) and total efficiency reached to 97%. ln control group, 32 cases were cured ( 46%) , 21 cases improved ( 30%) and 17 cases had no response ( 24%) and total efficiency was 76%. The cure rate and total efficiency of treatment group were significantly higher than that of control group (P ●CONCLUSION: The compound anisodine shows the beneficial effect on patients with paralytic strabismus. Compound anisodine may exert the effect via increasing SOD and reducing MDA.